RGS4 Inhibitor Shows Activity in Parkinson’s Disease Model
Thursday, 18 June 2015
RGS (regulator of G-protein signaling) proteins attenuate GPCR signals and provide an intriguing alternative to direct receptor targeting for modulating GPCR pathways. A recent effort led by Richard Neubig at Michigan State University (Blazer, et al ACS Chem Neurosci. 2015 Apr 20) provides a big boost to validation of RGS proteins as drug targets. Their
- Published in Neurodegenerative Diseases
No Comments
NEW! Orthogonal Pooled Screening – 5X Higher Efficiency, 80% Fewer Resources
Wednesday, 15 April 2015
Do what you’re good at with 5-fold greater efficiency—and leave the rest to us. We are pleased to announce that BellBrook Labs is partnering with the Lankenau Institute for Medical Research (LIMR) to provide access to an innovative Orthogonal Pooled Screening (OPS™) Platform. The OPS™ Platform provides drug discovery researchers with a drastically more efficient
- Published in News
BellBrook Labs Launches HTS Assay Platform for Targeting GPCR Regulatory Proteins
Tuesday, 09 October 2012
BellBrook Labs launched a comprehensive HTS assay reagent platform for “Regulators of G-protein Signaling” (RGS) protein, a family of proteins that shows promise as drug targets because of their emerging role in regulating G Protein-Coupled Receptors (GPCRs). The proprietary RGScreen technology, which combines kinetically enhanced recombinant proteins with BellBrook’s Transcreener GDP Assay, opens up new
- Published in Emerging Targets
